As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
Eliquis, the blockbuster blood thinner that has been a leading fixture in Bristol-Myers’ top line for years, now has FDA approved copycats.
Sold by an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
